Investigation of IDO1 and TDO2 expression in breast tumors by immunohistochemistry and real-time polymerase chain reaction methods

Basit Öğe Kaydı
dc.contributor.authorYildiz, Gulden
dc.contributor.authorBuyukbayram, Huseyin
dc.contributor.authorAlabalik, Ulas
dc.contributor.authorKeles, Ayse Nur
dc.date.accessioned2025-02-22T14:08:55Z
dc.date.available2025-02-22T14:08:55Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractAlthough diagnostic and therapeutic advances have been made in the treatment of breast cancer, the challenge of effectively controlling tumor progression persists. The objective of this study was to determine the relationship between IDO1 and TDO2 expression in breast cancer by immunohistochemistry and real-time polymerase chain reaction, hormone receptor status, Ki67 proliferation index, molecular classification, metastasis, and to investigate whether IDO1 and TDO2 expression can be used in combination with targeted therapy or as a marker to increase treatment efficacy in selected cases. The study included 74 cases of breast cancer and 14 cases of normal breast tissue as controls. All cases were analyzed for IDO1 and TDO2 by both immunohistochemistry and real-time polymerase chain reaction. The immunohistochemical analysis revealed that IDO1 immunoreactivity was significantly higher in tumor tissue compared to normal breast tissue. A statistically significant correlation was observed between IDO1 immunoreactivity and histologic subtypes. Furthermore, IDO1 gene expression was correlated with IDO1 immunoreactivity. TDO2 immune reactivity did not differ between tumor and non-tumor tissues and no correlation was found between histological subtypes. There was no correlation between TDO2 immunoreactivity and gene expression. The significant increase in IDO1 levels in tumor tissue and high positivity in age, HER2 positive and triple negative cases compared to other cases suggest that IDO1 inhibitors may be suitable for the target patient group in treatment selection.en_US
dc.identifier.doi10.1080/13102818.2024.2421291
dc.identifier.issn1310-2818
dc.identifier.issn1314-3530
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85208988179en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1080/13102818.2024.2421291
dc.identifier.urihttps://hdl.handle.net/11468/29716
dc.identifier.volume38en_US
dc.identifier.wosWOS:001343935200001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofBiotechnology & Biotechnological Equipmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectBreast carcinomaen_US
dc.subjectIDO1en_US
dc.subjectTDO2en_US
dc.subjectreal-time polymerase chain reactionen_US
dc.subjectimmunohistochemistryen_US
dc.titleInvestigation of IDO1 and TDO2 expression in breast tumors by immunohistochemistry and real-time polymerase chain reaction methodsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu